Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?

Bio-Rad Laboratories BIO is balancing improving digital PCR demand and a recurring diagnostics base against a valuation that already discounts meaningful execution. Restructuring offers another path to better profitability, but near-term revenue and earnings expectations remain restrained.

That mix makes the investment case less about whether the operating initiatives are working and more about whether their progress can justify the premium investors are already paying.

Bio-Rad's Digital PCR Growth Improves the Case

Digital PCR remains one of Bio-Rad’s clearer growth engines. Second-quarter 2026 currency-neutral digital PCR revenues increased 6% year over year, while instrument revenues rose more than 20% as the company reported competitive wins and conversions across geographies.

The Stilla Technologies portfolio also accelerated revenue growth and delivered margin performance ahead of management’s original expectations. Management expects digital PCR to help support a mid-single-digit sequential Life Science revenue increase from the third quarter to the fourth quarter of 2026.

BIO's Recurring Diagnostics Base Adds Stability

Clinical Diagnostics accounted for 60.5% of Bio-Rad’s 2025 revenues. In the second quarter of 2026, segment sales reached $399 million, up 2.6% reported and 0.3% on a currency-neutral basis, led by quality systems, diabetes and blood typing products.

Management expects quality controls and blood typing to support sequential improvement into the fourth quarter. That recurring-revenue base offers some stability while near-term growth across the company remains uneven.

Bio-Rad's 2026 Outlook Still Caps Growth

Bio-Rad expects full-year 2026 non-GAAP, currency-neutral revenues to range from a 3% decline to 0.5% growth. The company also projects a non-GAAP operating margin of 10% to 12%, reflecting an environment in which Life Science demand remains uneven.

The Zacks Consensus Estimate calls for 2026 sales of $2.532 billion and earnings of $9.14 per share, below 2025 sales of $2.583 billion and earnings of $9.92. The current-fiscal-year EPS estimate fell 3% over the past four weeks.

Image Source: Zacks Investment Research

BIO Trades at a Steep Earnings Multiple

BIO trades at 40.2X forward 12-month earnings, compared with 17.4X for the Zacks sub-industry. The stock also sits well above its own five-year median multiple of 28.8X, leaving a sizable premium to both benchmarks.

Bio-Rad’s peer set includes Danaher Corporation DHR, an industry reference point within the Medical - Products group. Bio-Techne Corporation TECH is also listed among BIO’s peers. Those comparisons add context to a valuation that already stands above the sub-industry benchmark.

Bio-Rad's Restructuring Could Lift 2027 Margins

Bio-Rad’s restructuring program is expected to produce $30 million to $35 million of annualized net cost savings after reinvestment, with the program substantially completed by the end of 2027.

Management expects the restructuring to add roughly 40 to 50 basis points of operating margin expansion in 2027. Product cost reductions, procurement leverage and higher-margin new products provide additional profitability levers beyond the savings program.

Based on short-term price targets offered by four analysts, the average price target for Bio-Rad comes to $341.25. The average price target represents a decline of 9.35% from the last closing price. 

Image Source: Zacks Investment Research

Bio-Rad's Style Scores Favor Patience

For investors considering a new position, the current setup leans toward patience rather than an aggressive purchase. Bio-Rad carries a Zacks Rank #3 (Hold), which can be consistent with holding a stock but lacks the stronger short-term signal attached to the top two ranks.

BIO has a Value Score of C, Growth Score of D, Momentum Score of D and VGM Score of D. The Style Score framework favors A or B grades alongside top Zacks Rank stocks, so Bio-Rad’s current readings do not provide that favorable confirmation despite its operating initiatives.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research